Precisely Tuned Inhibition of HIF Prolyl Hydroxylases Is Key for Cardioprotection After Ischemia
Open Access
- 16 April 2021
- journal article
- letter
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation Research
- Vol. 128 (8), 1208-1210
- https://doi.org/10.1161/circresaha.120.318216
Abstract
No abstract availableKeywords
Funding Information
- Deutsche Forschungsgemeinschaft (DFG Ka1269/13-1)
- Wellcome Trust (106241/Z/14/Z)
- Deutsche Forschungsgemeinschaft (GRK1816)
This publication has 5 references indexed in Scilit:
- Systemic silencing of Phd2 causes reversible immune regulatory dysfunctionJCI Insight, 2019
- Things get broken: the hypoxia-inducible factor prolyl hydroxylases in ischemic heart diseaseBasic Research in Cardiology, 2019
- Pharmacological targeting of the HIF hydroxylases – A new field in medicine developmentMolecular Aspects of Medicine, 2016
- HIF Hydroxylase Pathways in Cardiovascular Physiology and MedicineCirculation Research, 2015
- Cardiovascular remodelling in coronary artery disease and heart failureThe Lancet, 2014